Pharmaceutical News

RSS

Study reveals misuse of scientific evidence by opioid makers

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that makers and marketers of prescription opioid painkillers misused scientific evidence to advance five common and inaccurate claims about the safety and effectiveness of prescription opioids-;including that they were not addictive.

25 Oct 2024

Semaglutide may reduce Alzheimer's risk in diabetics

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease.

25 Oct 2024

Antibiotic for liver disease linked to emergence of antimicrobial resistant superbug

An international team of researchers has found that an antibiotic commonly prescribed for patients with liver disease, called rifaximin, has led to the global emergence of an almost untreatable form of the antimicrobial resistant superbug vancomycin-resistant enterococcus faecium (VRE), which frequently causes serious infections in hospitalized patients.

24 Oct 2024

Semaglutide may lower Alzheimer's risk in type 2 diabetes patients

Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

24 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

New chemical language model can predict dual-target drug candidates

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties.

23 Oct 2024

Advancements in antibody-drug conjugates transform cancer therapy

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.

22 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

New drug shows promise for motor neurone disease treatment

A pioneering study published in the International Journal of Molecular Sciences by researchers at Durham University has revealed promising results for a new treatment targeting motor neurone disease (MND).

22 Oct 2024

Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication

Researchers examine the association between prescriptions of diabetes drugs and the incidence of alcohol intoxication and opioid overdose.

22 Oct 2024

Affordability and supply remain critical to the success of long-lasting HIV drug

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, say global health specialists.

21 Oct 2024

Methadone more effective than buprenorphine in reducing treatment discontinuation

People with opioid use disorder in British Columbia who received methadone had a 37–40 per cent lower rate of treatment discontinuation compared with those who received buprenorphine/naloxone.

21 Oct 2024

Study suggests NSAIDs may lower postoperative delirium risk

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may help reduce patients' risk of postoperative delirium, according to a study presented at the ANESTHESIOLOGY® 2024 annual meeting.

20 Oct 2024

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

NNC2215, a glucose-sensitive insulin, offers improved glycemic control by dynamically adjusting to blood sugar levels, reducing hypoglycemia in diabetes care.

18 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

Accure Acne secures FDA clearance for long-term acne solution

Accure Acne, Inc.™, a pioneer in the development of innovative solutions for the treatment of acne, announced today that it has received a new FDA Clearance K242035 for the long-term treatment of mild to severe inflammatory acne vulgaris.

18 Oct 2024

Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease

Researchers identified Janus kinase inhibitors as a promising treatment for the severe drug-induced skin condition toxic epidermal necrolysis, by analyzing patient biopsies with deep visual proteomics.

17 Oct 2024

ALS drug shows promise in targeting glioblastoma stem cells

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable.

17 Oct 2024

Ozempic and similar drugs may lower risks for opioid and alcohol use disorders

A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.

17 Oct 2024

Rising concerns over benzodiazepine prescriptions in older stroke survivors

Although there has been a slight downward trend in the prescription of benzodiazepines (depressants that relieve anxiety, muscle spasms, produce sedation and reduce seizures) among older adults over the last decade, the rate of first-time prescriptions for these medications after an ischemic (clot-caused) stroke is still sizable, according to research published today in Stroke, the peer-reviewed scientific journal of the American Stroke Association, a division of the American Heart Association.

17 Oct 2024